Literature DB >> 32813916

Exercise-induced ventricular tachycardia in a case with hypertrophic cardiomyopathy taking cibenzoline.

Shinya Shiohira1, Mihoko Kawabata1,2, Masahiko Goya1, Shingo Maeda2, Tetsuo Sasano1, Kenzo Hirao2.   

Abstract

We report a 17-year-old woman with hypertrophic cardiomyopathy (HCM) successfully resuscitated from ventricular fibrillation while taking cibenzoline. During exercise-stress testing before implanting an implantable cardioverter-defibrillator, ventricular tachycardia was induced and thought to be a proarrhythmia due to the use-dependent effect of the Na channel blockade with cibenzoline. In patients with arrhythmogenic substrates such as HCM, it is critical to pay attention to the proarrhythmic effects of class I antiarrhythmic drugs while increasing heart rate.
© 2020 The Authors. Annals of Noninvasive Electrocardiology published by Wiley Periodicals LLC.

Entities:  

Keywords:  QRS duration; hypertrophic cardiomyopathy; proarrhythmia; sodium channel blocker; use-dependent; ventricular tachycardia

Year:  2020        PMID： 32813916      PMCID： PMC7816811          DOI： 10.1111/anec.12789

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN： 1082-720X            Impact factor:   1.468


  5 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

2.  Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy.

Authors:  M Hamada; Y Shigematsu; Y Hara; M Suzuki; T Ohtsuka; G Hiasa; A Ogimoto; H Saeki; J Suzuki; K Hiwada
Journal:  Jpn Circ J       Date:  2001-06

3.  Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade.

Authors:  S Ranger; M Talajic; R Lemery; D Roy; S Nattel
Journal:  Circulation       Date:  1989-05       Impact factor: 29.690

Review 4.  Proarrhythmia.

Authors:  P L Friedman; W G Stevenson
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

5.  Exercise-induced ventricular tachycardia in a case with hypertrophic cardiomyopathy taking cibenzoline.

Authors:  Shinya Shiohira; Mihoko Kawabata; Masahiko Goya; Shingo Maeda; Tetsuo Sasano; Kenzo Hirao
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-08-19       Impact factor: 1.468
  5 in total
  1 in total

1.  Exercise-induced ventricular tachycardia in a case with hypertrophic cardiomyopathy taking cibenzoline.

Authors:  Shinya Shiohira; Mihoko Kawabata; Masahiko Goya; Shingo Maeda; Tetsuo Sasano; Kenzo Hirao
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-08-19       Impact factor: 1.468
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.